What could an aducanumab approval mean for future Alzheimer's R&D?

What could an aducanumab approval mean for future Alzheimer's R&D?

Experts and industry watchers fully expect the FDA to approve Biogen’s controversial Alzheimer’s disease drug aducanumab—but not because it’s a game changer. In the words of one analyst, aducanumab won’t get the agency’s nod because its data are …
See Original Article

Should You Buy Stocks Now?

With Election Day behind us, many investors may be wondering whether now is a good time to buy stocks. Sure, political tension drags on and uncertainty remains. But market indexes have surged higher recently, suggesting the Street believes the worst of …
See Original Article

Sebi restores pre-covid cut-off time for mutual fund transactions

The Securities and Exchange Board of India (Sebi) has restored the pre-covid cut-off timings of mutual funds, effective 9 November. The regulator has sent a letter to industry body AMFI in this regard, a copy of which was seen by Mint. In April, Sebi had …
See Original Article

MBTA commuters not wearing masks face up to $300 fine

BOSTON (WHDH) – Commuters who fail to wear a face covering on any Massachusetts Bay Transportation Authority vehicle can face up to a $300 fine under Gov. Charlie Baker’s revised executive order. RELATED: Massachusetts’ new stay-at-home advisory, …
See Original Article

Economy added 638000 jobs in October as growth slows

The unemployment rate fell to 6.9 from 7.9 percent, according to the Bureau of Labor Statistics, which releases the monthly employment report from data gathered during the first half of the preceding month. Eleven million people remain …
See Original Article

Leave a Reply

Your email address will not be published. Required fields are marked *

This site uses Akismet to reduce spam. Learn how your comment data is processed.